Ever Supreme Bio Technology Co., Ltd (TPEX:6712)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
129.00
-1.50 (-1.15%)
Apr 28, 2026, 1:30 PM CST
-15.28%
Market Cap 11.30B
Revenue (ttm) 1.02B
Net Income (ttm) 429.43M
Shares Out 87.60M
EPS (ttm) 4.88
PE Ratio 26.43
Forward PE 20.98
Dividend 3.50 (2.68%)
Ex-Dividend Date Apr 16, 2026
Volume 449,537
Average Volume 251,706
Open 130.50
Previous Close 130.50
Day's Range 127.00 - 131.00
52-Week Range 127.00 - 188.00
Beta 0.52
RSI 21.74
Earnings Date Apr 14, 2026

About TPEX:6712

Ever Supreme Bio Technology Co., Ltd engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells in Taiwan. It operates in two segments: Cell Preparation Business and Other Operating Business segments. The company’s products include umbilical cord mesenchymal stem cells (UMC01), a drug candidate in Phase I clinical trials for the treatment of myocardial infarction and stroke. It also develops dendritic cell vaccine (ADCV01), a drug candidate in Phase II clinical trials for the ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 94
Stock Exchange Taipei Exchange
Ticker Symbol 6712
Full Company Profile

Financial Performance

In 2025, TPEX:6712's revenue was 1.02 billion, an increase of 8.96% compared to the previous year's 933.81 million. Earnings were 429.43 million, an increase of 16.93%.

Financial Statements

News

There is no news available yet.